Lisata and Marea merge to advance cardio and endocrine drugs
The all-stock merger pairs Lisata's oncology focus with Marea's mid-stage cardiovascular and endocrine pipeline, backed by $225 million in financing.
Lisata Therapeutics, a biotech focused on solid tumors, is merging with Marea Therapeutics, a company developing treatments for cardiovascular and endocrine diseases. The all-stock merger, announced alongside a $225 million financing package, will fund the continued development of Marea's two mid-stage drug candidates. The combined company will list on Wall Street under Lisata's name.
This deal marks a fresh start for Lisata after a previous acquisition attempt collapsed, resulting in significant layoffs and a lawsuit. The two companies' pipelines are complementary rather than overlapping, with Lisata bringing its oncology assets and Marea contributing its metabolic and cardiovascular programs. Both sources agree on the core terms and the strategic rationale, though Fierce Biotech emphasizes the troubled history leading to the merger, while BioPharma Dive focuses on the financial backing and pipeline potential.
Sources · 2
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.